Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00579592
Recruitment Status : Terminated (Higher than expected rate of acute rejection)
First Posted : December 24, 2007
Last Update Posted : June 26, 2012
Information provided by (Responsible Party):
University of Wisconsin, Madison

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Primary Completion Date : March 2007
  Study Completion Date : April 2007